NCT07808515
A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)
StatusNot Yet Recruiting
PhasePhase 2
SponsorRegeneron Pharmaceuticals
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Minor Start date pushed from Oct 15, 2026 to Nov 13, 2026
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Objective Response Rate (ORR) by blinded independent central review (BICR) per Composite Response Criteria
Timeframe: Up to approximately 3 years
Secondary (11)
Duration of Response (DOR) by BICR per Composite Response Criteria
Time to Response (TTR) by BICR per Composite Response Criteria
Best Overall Response (BOR) of Complete Response (CR) by BICR per composite Response Criteria
Progression-Free Survival (PFS) by BICR per Composite Response Criteria
Objective Response by investigator review per Composite Response Criteria
Show 6 moreShow less
DOR by investigator review per Composite Response Criteria
TTR by investigator review per Composite Response Criteria
Complete Response (CR) by investigator review per Composite Response Criteria
PFS by investigator review per Composite Response Criteria
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs
Arms and interventions
Arm AExperimental
Arm BExperimental
Arm CExperimental
Subsequent Therapy ArmExperimental
Drugs: Cemiplimab, Vidutolimod, Fianlimab